Background: Coronavirus disease (Covid-19) has impacted many countries' health care and their economic progress within no time. This Pandemic situation demands a safe and cost-effective treatment as early as possible to prevent any further damage.

Objective: To clinically evaluate the safety and efficacy of T-AYU-HM Premium Tablets and Onion Steam Vaporisation in Mild to Moderate Covid-19 patients.

Methodology: It is an Open-label, Single-arm type of study conducted in mild to moderate level patients infected with the coronavirus. The study conducted on 30 patients who provided their informed consent. Ayush standard mark anti sickling tablet T-AYU-HM Premium 600mg BD and Onion steam vaporisation OD for 21 days prescribed to patients under home quarantine.  Both clinical and pathological changes were recorded on the baseline, 5th and 21st day of the trial. Adverse events reported by the patients and those observed by the principal investigator were recorded.

 

Result: All the patients recovered clinically and no untoward effects were observed during this trial period. A significant reduction (p<0.05) in the pathological parameters like C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and lactate dehydrogenase (LDH) was observed. The oxygen saturation (SpO2) level remained well maintained during the treatment suggesting that neither further complications nor hospitalisation were required.

 

Conclusion: The treatment regimen T-AYU-HM Premium and Onion vaporisation impact on clinical and pathological parameters suggest it is safe and indicates its potential candidacy in treatment of coronavirus.

 

Keywords: Coronavirus, T-AYU-HM Premium, Onion vaporisation, CRP, ESR LDH